Dutasteride 0.5 mg/day lowers scalp DHT levels by only 50% (but 2.5 mg/day lowers scalp DHT by 80%).
    Finasteride/Dutasteride 2/21/2025

    From the encyclopedia
    Dutasteride →

    5-alpha reductase inhibitor that blocks both enzyme types, a stronger DHT blocker than finasteride

    Finasteride →

    Popular 5-alpha reductase inhibitor that lowers DHT, taken as a pill or used topically

    RU58841 →

    Experimental topical anti-androgen sold as a research chemical

    At a glance
    In this educational post, the primary subjects mentioned are
    💊 Dutasteride (oral) 0.5 mg daily
    💊 Dutasteride (oral) 2.5 mg daily
    the tone is 😐 neutral.

    Other terms

    Dutasteride at 2.5 mg/day reduces scalp DHT by 80%, while 0.5 mg/day reduces it by 50%, with minimal difference in side effects. Users often combine it with finasteride, RU58841, and minoxidil for better hair loss management, though side effects like dry skin and pimples are noted.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

    Related Research

    6 / 6 results

      research CLINICAL UPDATES IN HAIR

      19 citations , January 1997 in “Dermatologic Clinics”
      This chapter reviews various antiandrogens and androgen inhibitors, detailing their mechanisms, uses, and side effects, with a focus on spironolactone, finasteride, dutasteride, and oral contraceptives.

      research Antiandrogens and Androgen Inhibitors

      November 2020 in “Elsevier eBooks”
      This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.

      research Hair growth and rejuvenation: An overview

      81 citations , June 2010 in “Journal of Dermatological Treatment”
      This review discusses recent advancements in hair rejuvenation strategies and assesses the potential of herbal drugs as safer alternatives, but reports no new clinical results.